PMID- 32186467
OWN - NLM
STAT- MEDLINE
DCOM- 20210810
LR  - 20210810
IS  - 1784-973X (Electronic)
IS  - 0001-5385 (Linking)
VI  - 75
IP  - 8
DP  - 2020 Dec
TI  - Impact of sacubitril/valsartan treatment on depression and anxiety in heart 
      failure with reduced ejection fraction.
PG  - 774-782
LID - 10.1080/00015385.2020.1730577 [doi]
AB  - Background: In patients with heart failure (HF), depression and anxiety disorders 
      are common and associated with adverse outcomes. Sacubitril/valsartan, which is 
      an angiotensin receptor neprilysin inhibitor (ARNI), has been shown to reduce 
      mortality and hospitalisation in patients with heart failure with reduced 
      ejection fraction (HFrEF). However, its effects on depression and anxiety levels 
      remain unclear.Methods: Sacubitril/valsartan was initiated in 115 symptomatic 
      patients with HFrEF receiving an optimal medical treatment with angiotensin 
      inhibition. Patients underwent 6-minute walk test (6-MWT), The Beck Depression 
      Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI) were administered at the 
      switching to ARNI and at the third-month follow-up of the maximum 
      sacubitril/valsartan dose.Results: A significant improvement was observed in 
      BDI-II and BAI scores when compared before and after the sacubitril/valsartan 
      treatment (13.7 +/- 9.7 to 7.6 +/- 3.8, p < 0.001 and 13.3 +/- 8.9 to 8.1 +/- 4.1, 
      p < 0.001, respectively). The 6-MWT distance significantly increased from 
      213 +/- 95 to 327 +/- 118 mt (p < 0.001). Overall, the patients exhibited a 
      significant functional improvement following the initiation of 
      sacubitril/valsartan: 27% of the patients improved by two New York Heart 
      Association (NYHA) classes, 52% improved by one NYHA functional class, and 31% 
      remained stable.Conclusion: In patients with HFrEF, the switch from 
      angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy 
      to sacubitril/valsartan resulted in a significant improvement in both depression, 
      anxiety symptoms and functional statuses.
FAU - Dereli, Seckin
AU  - Dereli S
AUID- ORCID: 0000-0003-0090-3835
AD  - Deparment of Cardiology, Faculty of Medicine, Ordu University, Ordu, Turkey.
FAU - Kilincel, Oguzhan
AU  - Kilincel O
AD  - Department of Psychiatry, Sakarya Yenikent State Hospital, Sakarya, Turkey.
FAU - Cerik, Idris Bugra
AU  - Cerik IB
AD  - Deparment of Cardiology, Faculty of Medicine, Ordu University, Ordu, Turkey.
FAU - Kaya, Ahmet
AU  - Kaya A
AD  - Deparment of Cardiology, Faculty of Medicine, Ordu University, Ordu, Turkey.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200318
PL  - England
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aminobutyrates/*therapeutic use
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Anxiety/*complications
MH  - Biphenyl Compounds/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Depression/*complications
MH  - Drug Combinations
MH  - Female
MH  - Heart Failure/complications/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Stroke Volume/*physiology
MH  - Treatment Outcome
MH  - Valsartan/*therapeutic use
MH  - Ventricular Function, Left/physiology
OTO - NOTNLM
OT  - Sacubitril/valsartan
OT  - anxiety
OT  - depression
OT  - heart failure
EDAT- 2020/03/19 06:00
MHDA- 2021/08/11 06:00
CRDT- 2020/03/19 06:00
PHST- 2020/03/19 06:00 [pubmed]
PHST- 2021/08/11 06:00 [medline]
PHST- 2020/03/19 06:00 [entrez]
AID - 10.1080/00015385.2020.1730577 [doi]
PST - ppublish
SO  - Acta Cardiol. 2020 Dec;75(8):774-782. doi: 10.1080/00015385.2020.1730577. Epub 
      2020 Mar 18.